بدائل البحث:
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
-
1
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
منشور في 2025"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …"
-
2
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
منشور في 2025"…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …"
-
3
-
4
Candidates from the RF method. The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively....
منشور في 2025"…The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively. …"
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
12
-
13
-
14
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
منشور في 2025الموضوعات: -
15
Baseline patient characteristics across neutralizing monoclonal antibody trials.
منشور في 2025الموضوعات: -
16
-
17
-
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
19
-
20